Contrôle de l’asthme chez l’adulte en Algérie. Comparaison avec les autres pays d’Afrique du Nord et du Moyen Orient

Over-prescription of short-acting β2-agonists remains a serious health concern in Kenya: results from the SABINA III study

“…Consequently, the burden of asthma in Kenya was high, with 61.5% of patients experiencing ≥ 1 severe exacerbation in the previous 12 months. However, our findings are aligned with previous reports from Africa documenting suboptimal asthma control [ 21 , 51 – 53 ]. Indeed, results from the Epidemiological Study on the Management of Asthma in Asthmatic Middle East Adult Population, a large-scale cross-sectional epidemiological study in 7236 patients that included three African countries (Algeria, Egypt, and Tunisia), reported that asthma was only controlled in approximately one-third of all patients [ 54 ].…”

“…High rates of out-of-pocket expenditure for outpatient services, accounting for approximately 78% of the total household expenditure in Kenya [ 16 ], have further reduced the affordability of essential asthma medications, such as inhaled corticosteroids (ICS). Moreover, easy access to short-acting β 2 -agonist (SABA) relievers, coupled with the nonavailability of ICS-containing controller medication in many African countries, including Kenya [ 17 ], may explain the low levels of asthma control reported across Africa [ 18 – 21 ]. Notably, SABA overuse is globally associated with an increased risk of exacerbations, hospitalizations, and even mortality [ 22 – 25 ].…”